Your browser doesn't support javascript.
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Anna, François; Goyard, Sophie; Lalanne, Ana Ines; Nevo, Fabien; Gransagne, Marion; Souque, Philippe; Louis, Delphine; Gillon, Véronique; Turbiez, Isabelle; Bidard, François-Clément; Gobillion, Aline; Savignoni, Alexia; Guillot-Delost, Maude; Dejardin, François; Dufour, Evelyne; Petres, Stéphane; Richard-Le Goff, Odile; Choucha, Zaineb; Helynck, Olivier; Janin, Yves L; Escriou, Nicolas; Charneau, Pierre; Perez, Franck; Rose, Thierry; Lantz, Olivier.
  • Anna F; Theravectys, Paris, France.
  • Goyard S; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France.
  • Lalanne AI; INSERM 1221, Institut Pasteur, Paris, France.
  • Nevo F; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
  • Gransagne M; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Souque P; Theravectys, Paris, France.
  • Louis D; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France.
  • Gillon V; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France.
  • Turbiez I; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
  • Bidard FC; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Gobillion A; Direction of the Clinical Research, Institut Curie, Paris, France.
  • Savignoni A; Direction of the Clinical Research, Institut Curie, Paris, France.
  • Guillot-Delost M; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Dejardin F; Medical Oncology Department, Institut Curie, Paris, France.
  • Dufour E; UVSQ, Paris-Saclay University, Saint-Cloud, France.
  • Petres S; Biometry, Institut Curie, Paris, France.
  • Richard-Le Goff O; Biometry, Institut Curie, Paris, France.
  • Choucha Z; Centre d'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.
  • Helynck O; INSERM U932, PSL University, Institut Curie, Paris, France.
  • Janin YL; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Escriou N; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Charneau P; Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.
  • Perez F; Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, France.
  • Rose T; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France.
  • Lantz O; Unit of Chemistry and Biocatalysis, Institut Pasteur, CNRS UMR 3523, Paris, France.
Eur J Immunol ; 51(1): 180-190, 2021 01.
Article in English | MEDLINE | ID: covidwho-1023283
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
Semantic information from SemMedBD (by NLM)
1. Immune PROCESS_OF Persons
Subject
Immune
Predicate
PROCESS_OF
Object
Persons
2. Immune PROCESS_OF Persons
Subject
Immune
Predicate
PROCESS_OF
Object
Persons
ABSTRACT
Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high-throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 1847 participants working in three sites of an institution in Paris conurbation. In May-July 2020, 11% (95% confidence interval [CI] 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins, and 9.5% (95% CI 8.2-11.0) were neutralizer in pseudo-typed virus assays. The prevalence of seroconversion was 11.6% (95% CI 10.2-13.2) when considering positivity in at least one assay. In 5% of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4-8 weeks after the first sampling, anti-N and anti-S IgG titers and neutralization activity in pseudo-virus assay declined by 31%, 17%, and 53%, resulting thus in half-life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral Type of study: Risk factors Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Eur J Immunol Year: 2021 Document Type: Article Affiliation country: Eji.202049058

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral Type of study: Risk factors Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Eur J Immunol Year: 2021 Document Type: Article Affiliation country: Eji.202049058